Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04421027 · OUTCOME

Duration of Hospitalization

A Study of Baricitinib (LY3009104) in Participants With COVID-19 · Source last updated 2022-07-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
LEAST_SQUARES_MEAN
Unit
days
Interval / dispersion
Standard Error
Time frame
Days 1 to Day 28

What was measured

Duration of hospitalization.

Analysis population: All participants randomly assigned to study intervention. Participants with missing baseline ordinal scale were excluded.

Groups in this outcome

Placebo + SOC

Placebo administered orally QD with standard of care.

Baricitinib + SOC

4 mg baricitinib administered orally QD with standard of care.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Placebo + SOC756
Baricitinib + SOC762

Reported measurements

Source class 1
Values in days · Interval/dispersion: Standard Error
GroupValueSpreadLowerUpperComment
Placebo + SOC13.70.40Not reportedNot reportedNot reported
Baricitinib + SOC12.90.40Not reportedNot reportedNot reported

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

  1. ci Lower Limit
    -1.6
    ci Num Sides
    TWO_SIDED
    ci Pct Value
    95
    ci Upper Limit
    0.0
    dispersion Type
    STANDARD_ERROR_OF_MEAN
    dispersion Value
    0.408
    group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    SUPERIORITY
    p Value
    0.0626
    param Type
    LS Mean Difference (Net)
    param Value
    -0.76
    statistical Method
    ANOVA
Complete source fields
analyses
  1. ci Lower Limit
    -1.6
    ci Num Sides
    TWO_SIDED
    ci Pct Value
    95
    ci Upper Limit
    0.0
    dispersion Type
    STANDARD_ERROR_OF_MEAN
    dispersion Value
    0.408
    group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    SUPERIORITY
    p Value
    0.0626
    param Type
    LS Mean Difference (Net)
    param Value
    -0.76
    statistical Method
    ANOVA
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        0.40
        value
        13.7
      2. group Id
        OG001
        spread
        0.40
        value
        12.9
denoms
  1. counts
    1. group Id
      OG000
      value
      756
    2. group Id
      OG001
      value
      762
    units
    Participants
description
Duration of hospitalization.
dispersion Type
Standard Error
groups
  1. description
    Placebo administered orally QD with standard of care.
    id
    OG000
    title
    Placebo + SOC
  2. description
    4 mg baricitinib administered orally QD with standard of care.
    id
    OG001
    title
    Baricitinib + SOC
param Type
LEAST_SQUARES_MEAN
population Description
All participants randomly assigned to study intervention. Participants with missing baseline ordinal scale were excluded.
reporting Status
POSTED
time Frame
Days 1 to Day 28
title
Duration of Hospitalization
type
SECONDARY
unit Of Measure
days

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice